• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Quality of life should be the primary outcome for disease modifying therapy trials in MS-No.

作者信息

Strijbis Emm, Koch M W, de Jong B A

机构信息

Department of Neurology, MS Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.

Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada.

出版信息

Mult Scler. 2023 Aug;29(9):1066-1067. doi: 10.1177/13524585231182708. Epub 2023 Jul 25.

DOI:10.1177/13524585231182708
PMID:37489564
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10413779/
Abstract
摘要

相似文献

1
Quality of life should be the primary outcome for disease modifying therapy trials in MS-No.生活质量应是多发性硬化症疾病修正治疗试验的主要结果——否。
Mult Scler. 2023 Aug;29(9):1066-1067. doi: 10.1177/13524585231182708. Epub 2023 Jul 25.
2
Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary.
Mult Scler. 2023 Aug;29(9):1068-1069. doi: 10.1177/13524585231182702. Epub 2023 Jul 25.
3
Quality of life should be the primary outcome for disease-modifying therapy trials in MS-Yes.
Mult Scler. 2023 Aug;29(9):1064-1065. doi: 10.1177/13524585231182705. Epub 2023 Jul 25.
4
Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go?多发性硬化症中疾病修饰疗法的停用：我们该留下还是离开？
JAMA Neurol. 2021 Jul 1;78(7):787-788. doi: 10.1001/jamaneurol.2021.0764.
5
Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.复发缓解型多发性硬化症患者的真实世界疾病修正疗法使用情况：来自瑞士多发性硬化症登记处的横断面数据。
Mult Scler Relat Disord. 2022 Apr;60:103706. doi: 10.1016/j.msard.2022.103706. Epub 2022 Feb 21.
6
Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews.二羟麦角隐亭富马酸盐治疗复发性多发性硬化症患者的健康相关生活质量：采用患者访谈进行定性研究的结果。
Adv Ther. 2022 Jul;39(7):3199-3213. doi: 10.1007/s12325-022-02164-8. Epub 2022 May 13.
7
Teriflunomide for multiple sclerosis.特立氟胺用于治疗多发性硬化症。
Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2.
8
Discontinuing disease-modifying multiple sclerosis therapies.
Lancet Neurol. 2023 Jul;22(7):543-545. doi: 10.1016/S1474-4422(23)00200-4.
9
Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects.多发性硬化症：流行病学、临床及治疗方面
Neuroimaging Clin N Am. 2017 May;27(2):195-204. doi: 10.1016/j.nic.2016.12.001.
10
Current disease-modifying therapies in multiple sclerosis.目前用于治疗多发性硬化症的疾病修正疗法。
Semin Neurol. 2003 Jun;23(2):133-46. doi: 10.1055/s-2003-41138.

引用本文的文献

1
Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis.临床研究证据表明，疾病修正疗法对多发性硬化症的生活质量有影响：系统分析。
J Neurol. 2024 Jun;271(6):3131-3141. doi: 10.1007/s00415-024-12366-5. Epub 2024 Apr 16.

本文引用的文献

1
The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.多发性硬化症进展期临床试验中的 MSIS-29 和 SF-36 作为结局指标。
Mult Scler. 2022 Sep;28(10):1606-1619. doi: 10.1177/13524585221105465.
2
Patient-reported outcomes in the spotlight.患者报告的结局成为焦点。
Lancet Neurol. 2019 Nov;18(11):981. doi: 10.1016/S1474-4422(19)30357-6.
3
Can Methods Developed for Interpreting Group-level Patient-reported Outcome Data be Applied to Individual Patient Management?用于解释群组水平患者报告结局数据的方法能否应用于个体患者管理？
Med Care. 2019 May;57 Suppl 5 Suppl 1(Suppl 5 1):S38-S45. doi: 10.1097/MLR.0000000000001111.
4
Is there a genuine placebo effect in acute depression treatments? A reassessment of regression to the mean and spontaneous remission.急性抑郁症治疗中是否存在真正的安慰剂效应？对均值回归和自发缓解的重新评估。
BMJ Evid Based Med. 2020 Apr;25(2):46-48. doi: 10.1136/bmjebm-2019-111161. Epub 2019 Apr 11.
5
Data mining for response shift patterns in multiple sclerosis patients using recursive partitioning tree analysis.应用递归分区树分析挖掘多发性硬化症患者的反应转移模式数据。
Qual Life Res. 2011 Dec;20(10):1543-53. doi: 10.1007/s11136-011-0004-7. Epub 2011 Sep 11.
6
Patient-reported quality of life in multiple sclerosis differs between cultures and countries: a cross-sectional Austrian-German-Polish study.多发性硬化症患者的生活质量在不同文化和国家之间存在差异：一项奥地利-德国-波兰的横断面研究。
Mult Scler. 2011 Apr;17(4):478-86. doi: 10.1177/1352458510391341. Epub 2010 Dec 9.
7
'Equivalence' and the translation and adaptation of health-related quality of life questionnaires.“等效性”以及健康相关生活质量问卷的翻译与改编
Qual Life Res. 1997 Apr;6(3):237-47. doi: 10.1023/a:1026410721664.